{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:43:55Z","timestamp":1791420235222,"version":"4.3.3"},"reference-count":40,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:p>Therapeutic drug monitoring (TDM) aims to integrate drug measurement results into clinical decision making. The basic rules apply when using TDM in neonates (aminoglycosides, vancomycin, phenobarbital, digoxin), but additional factors should also be taken into account. First, due to both pharmacokinetic variability and non-pharmacokinetic factors, the correlation between dosage and concentration is poor in neonates, but can be overcome with the use of more complex, validated dosing regimens. Second, the time to reach steady state is prolonged, especially when no loading dose is used. Consequently, the timing of TDM sampling is important in this population. Third, the target concentration may be uncertain (vancomycin) or depend on specific factors (phenobarbital during whole body cooling). Finally, because of differences in matrix composition (eg, protein, bilirubin), assay-related inaccuracies may be different in neonates. We anticipate that complex validated dosing regimens, with subsequent TDM sampling and Bayesian forecasting, are the next step in tailoring pharmacotherapy to individual neonates.<\/jats:p>","DOI":"10.1136\/archdischild-2013-305309","type":"journal-article","created":{"date-parts":[[2016,1,24]],"date-time":"2016-01-24T01:18:34Z","timestamp":1453598314000},"page":"377-381","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":54,"title":["Therapeutic drug monitoring in neonates"],"prefix":"10.1136","volume":"101","author":[{"given":"Steven","family":"Pauwels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Allegaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,1,22]]},"reference":[{"key":"key-10.1136\/archdischild-2013-305309-1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clp.2011.12.009","article-title":"Therapeutic drug monitoring\u2014the appropriate use of drug level measurement in the care of the neonate","volume":"39","author":"Young","year":"2012","journal-title":"Clin Perinatol"},{"key":"key-10.1136\/archdischild-2013-305309-2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00003088-200948020-00001","article-title":"Therapeutic drug monitoring of aminoglycosides in neonates","volume":"48","author":"Touw","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"key-10.1136\/archdischild-2013-305309-3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/pan.12176","article-title":"Neonatal clinical pharmacology","volume":"24","author":"Allegaert","year":"2014","journal-title":"Paediatr Anaesth"},{"key":"key-10.1136\/archdischild-2013-305309-4","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"key":"key-10.1136\/archdischild-2013-305309-5","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.2174\/1381612811209023119","article-title":"Pharmacokinetics of drugs in neonates: pattern recognition beyond compound specific observations","volume":"18","author":"Smits","year":"2012","journal-title":"Curr Pharm Des"},{"key":"key-10.1136\/archdischild-2013-305309-6","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/j.1365-2125.2012.04406.x","article-title":"External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings","volume":"75","author":"Zhao","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"key-10.1136\/archdischild-2013-305309-7","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s11095-013-1197-y","article-title":"A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates","volume":"31","author":"De Cock","year":"2014","journal-title":"Pharm Res"},{"key":"key-10.1136\/archdischild-2013-305309-8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/archdischild-2013-303721","article-title":"Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling","volume":"99","author":"Admiraal","year":"2014","journal-title":"Arch Dis Child"},{"key":"key-10.1136\/archdischild-2013-305309-9","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.clinbiochem.2014.05.018","article-title":"The impact of therapeutic drug monitoring in neonatal clinical pharmacology","volume":"47","author":"van den Anker","year":"2014","journal-title":"Clin Biochem"},{"key":"key-10.1136\/archdischild-2013-305309-10","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/FTD.0000000000000071","article-title":"Impact of clinical decision support guidelines on therapeutic drug monitoring of gentamicin in newborns","volume":"36","author":"Fonzo-Christe","year":"2014","journal-title":"Ther Drug Monit"},{"key":"key-10.1136\/archdischild-2013-305309-11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/BF03258374","article-title":"Nonpharmacokinetic clinical factors affecting aminoglycoside therapeutic precision","volume":"4","author":"Jelliffe","year":"1992","journal-title":"Drug Invest"},{"key":"key-10.1136\/archdischild-2013-305309-12","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/archdischild-2013-304887","article-title":"Intravenous drug delivery in neonates: lessons learnt","volume":"99","author":"Sherwin","year":"2014","journal-title":"Arch Dis Child"},{"issue":"(P12)","key":"key-10.1136\/archdischild-2013-305309-13","first-page":"6.e1","article-title":"Standard or individualised gentamicin dosing for neonates?","volume":"100","author":"Caldwell","year":"2015","journal-title":"Arch Dis Child"},{"key":"key-10.1136\/archdischild-2013-305309-14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/11595640-000000000-00000","article-title":"Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance","volume":"51","author":"De Cock","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"key-10.1136\/archdischild-2013-305309-15","doi-asserted-by":"crossref","first-page":"6344","DOI":"10.1128\/AAC.01157-15","article-title":"Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice","volume":"59","author":"Smits","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.1136\/archdischild-2013-305309-16","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1067\/mcp.2002.123595","article-title":"Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring","volume":"71","author":"de Hoog","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.1136\/archdischild-2013-305309-17","doi-asserted-by":"crossref","first-page":"F278","DOI":"10.1136\/archdischild-2014-307725","article-title":"Neonatal vancomycin trough level audit using British National Formulary for Children dosing","volume":"100","author":"Petrie","year":"2015","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"key-10.1136\/archdischild-2013-305309-18","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/archdischild-2014-306873","article-title":"Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: a French national survey","volume":"100","author":"Leroux","year":"2015","journal-title":"Arch Dis Child"},{"key":"key-10.1136\/archdischild-2013-305309-19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/17512433.2015.1060124","article-title":"How to use vancomycin optimally in neonates: remaining questions","volume":"8","author":"Jacqz-Aigrain","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"key-10.1136\/archdischild-2013-305309-20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/archdischild-2012-302765","article-title":"Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring","volume":"98","author":"Zhao","year":"2013","journal-title":"Arch Dis Child"},{"key":"key-10.1136\/archdischild-2013-305309-21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12887-015-0359-y","article-title":"High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: implications for research and dissemination","volume":"15","author":"Metsvaht","year":"2015","journal-title":"BMC Pediatr"},{"key":"key-10.1136\/archdischild-2013-305309-22","first-page":"CD005091","article-title":"One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates","volume":"9","author":"Rao","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.1136\/archdischild-2013-305309-23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1128\/AAC.00694-11","article-title":"Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants","volume":"56","author":"Mohamed","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.1136\/archdischild-2013-305309-24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cca.2014.12.012","article-title":"Novel LC-MS\/MS method for plasma vancomycin: comparison with immunoassays and clinical impact","volume":"441","author":"Oyaert","year":"2015","journal-title":"Clin Chim Acta"},{"key":"key-10.1136\/archdischild-2013-305309-25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40262-012-0004-y","article-title":"Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approach","volume":"51","author":"van den Broek","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"key-10.1136\/archdischild-2013-305309-26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00431-006-0189-x","article-title":"Population clinical pharmacology of children: modelling covariate effects","volume":"165","author":"Anderson","year":"2006","journal-title":"Eur J Pediatr"},{"key":"key-10.1136\/archdischild-2013-305309-27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/FTD.0000000000000043","article-title":"Comparability and imprecision of 8 frequently used commercially available immunoassays for therapeutic drug monitoring","volume":"36","author":"Shipkova","year":"2014","journal-title":"Ther Drug Monit"},{"key":"key-10.1136\/archdischild-2013-305309-28","unstructured":"Belgian External Quality Evaluation Scheme, Scientific Institute of Public Health (WIV), global report TDM 2014\/1, May 09 2014 p 34\u201335. http:\/\/www.wiv-isp.be\/QML\/activities\/external_quality\/rapports\/_down\/therapeutic_drug_monitoring\/2014\/14-1-TDM-F.pdf (accessed 21 December 2015)."},{"key":"key-10.1136\/archdischild-2013-305309-29","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/FTD.0b013e3182866a99","article-title":"The importance of knowing how vancomycin is measured when interpreting its pharmacokinetic results","volume":"35","author":"Zhao","year":"2013","journal-title":"Ther Drug Monit"},{"key":"key-10.1136\/archdischild-2013-305309-30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1128\/AAC.00636-08","article-title":"Microanalysis of beta-lactam antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates","volume":"53","author":"Ahsman","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.1136\/archdischild-2013-305309-31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jchromb.2014.01.035","article-title":"A simple quantitative method analysing amikacin, gentamicin, and vancomycin levels in human newborn plasma using ion-pair liquid chromatography\/tandem mass spectrometry and its applicability to a clinical study","volume":"951\u2013952","author":"Bijleveld","year":"2014","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"key-10.1136\/archdischild-2013-305309-32","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cca.2012.01.008","article-title":"Fast and simple LC-MS\/MS method for quantifying plasma voriconazole","volume":"413","author":"Pauwels","year":"2012","journal-title":"Clin Chim Acta"},{"key":"key-10.1136\/archdischild-2013-305309-33","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/adc.2009.177592","article-title":"Facilitating pharmacokinetic studies in children: a new use of dried blood spots","volume":"95","author":"Patel","year":"2010","journal-title":"Arch Dis Child"},{"key":"key-10.1136\/archdischild-2013-305309-34","first-page":"1","article-title":"Performance of a dosage individualization table for extended interval gentamicin in neonates beyond the first week of life","author":"Dersch-Mills","year":"2015","journal-title":"J Matern Fetal Neonatal Med"},{"key":"key-10.1136\/archdischild-2013-305309-35","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/cid\/cis446","article-title":"Editorial commentary: antifungal therapeutic drug monitoring progress: getting it right the first time","volume":"55","author":"Andes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key-10.1136\/archdischild-2013-305309-36","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(14)70017-8","article-title":"Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation","volume":"15","author":"Groll","year":"2014","journal-title":"Lancet Oncol"},{"key":"key-10.1136\/archdischild-2013-305309-37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00007691-200202000-00002","article-title":"Potential benefit of Bayesian forecasting for therapeutic drug monitoring in neonates","volume":"24","author":"Pons","year":"2002","journal-title":"Ther Drug Monit"},{"key":"key-10.1136\/archdischild-2013-305309-38","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.cmi.2015.05.002","article-title":"Optimization of dosing regimens and dosing in special populations","volume":"21","author":"Sime","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"key-10.1136\/archdischild-2013-305309-39","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0924-8579(02)00188-7","article-title":"TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients","volume":"20","author":"Pea","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"key-10.1136\/archdischild-2013-305309-40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12911-014-0128-0","article-title":"A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children","volume":"15","author":"Hamberg","year":"2015","journal-title":"BMC Med Inform Decis Mak"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2013-305309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:36:31Z","timestamp":1601109391000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2013-305309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,22]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,3,17]]},"published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1136\/archdischild-2013-305309"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2013-305309","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,22]]}}}